1. Search Result
Search Result
Results for "

immune disorders

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

4

Screening Libraries

1

Biochemical Assay Reagents

4

Natural
Products

1

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150747A

    IFNAR Inflammation/Immunology
    ODN 6016 sodium is a CpG-A oligonucleotides. ODN 6016 sodium can induce IFN-α production, and can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .
    ODN 6016 sodium
  • HY-145429
    IL-17A modulator-2
    1 Publications Verification

    Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
    IL-17A modulator-2
  • HY-145430

    Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
    IL-17A modulator-1
  • HY-32343
    Secalciferol
    4 Publications Verification

    (24R)-24,25-Dihydroxyvitamin D3

    Endogenous Metabolite VD/VDR Metabolic Disease Inflammation/Immunology
    Secalciferol ((24R)-24,25-Dihydroxyvitamin D3) is the major active metabolite of Vitamin D. Secalciferol activates vitamin D receptor (VDR) with an EC50 value of 150 nM. Secalciferol is involved in a wide range of biological functions such as calcium homeostasis, cellular differentiation and proliferation processes, as well as other functions related to the immune system, which is promising for research of rickets, osteomalacia, hypercalcemia and autoimmune disorders .
    Secalciferol
  • HY-401475

    PKC Cardiovascular Disease Inflammation/Immunology Cancer
    Protein kinase inhibitor 9 (Compound example 175) is an inhibitor of serine/threonine and tyrosine kinase activity. Protein kinase inhibitor 9 can be used for the research of cancer, hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders .
    Protein kinase inhibitor 9
  • HY-137122

    PIN1 Inflammation/Immunology
    3-Pyridine toxoflavin (compound 49) is a PIN1 inhibitor. 3-Pyridine toxoflavin can be used for the research of immune disease proliferative disorder .
    3-Pyridine toxoflavin
  • HY-160548

    mTOR Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders .
    mTOR inhibitor-18
  • HY-150747

    IFNAR Inflammation/Immunology
    ODN 6016 is a CpG-A oligonucleotides. ODN 6016 can induce IFN-α production, can be used for researching immune disorders including immunodeficiency caused by HIV-1. ODN 6016 sequence: T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G .
    ODN 6016
  • HY-142932

    Btk Neurological Disease Inflammation/Immunology Cancer
    BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .
    BTK-IN-6
  • HY-147574

    TAM Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .
    Axl-IN-7
  • HY-160168

    Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-139331

    Proteasome Neurological Disease Inflammation/Immunology Cancer
    20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .
    20S Proteasome-IN-1
  • HY-107560

    Histamine Receptor Cancer
    4-Methylhistamine (dihydrochloride) is the potent agonist of histamine 4 receptor (H4R). 4-Methylhistamine (dihydrochloride) has the potential for the research of immune-related diseases such as cancer and autoimmune disorders .
    4-Methylhistamine dihydrochloride
  • HY-W580721

    Histamine Receptor Inflammation/Immunology Cancer
    4-Methylhistamine is a potent agonist of histamine 4 receptor (H4R). 4-Methylhistamine has the potential for the research of immune-related diseases such as cancer and autoimmune disorders .
    4-Methylhistamine
  • HY-157746

    DNA/RNA Synthesis Inflammation/Immunology Cancer
    CTPS1-IN-1 (compound R80) is a CTPS1 inhibitor. CTPS1-IN-1 has the potential to research cancer (such as promoting vascular injury or surgical recovery) and immune system diseases (such as rejection of transplanted cells and tissues, transplant-related diseases or disorders, allergies, and autoimmune diseases) .
    CTPS1-IN-1
  • HY-168625

    Molecular Glues Inflammation/Immunology
    VAV1 degrader-3 (Example 185) is an orally active VAV1 molecular glue degrader (DC50: 7 nM). VAV1 degrader-3 reduces immune cell activation, immune cell proliferation and the production of various cytokines. VAV1 degrader-3 can be used for research of inflammatory or autoimmune disorder. VAV1 degrader-3 inhibits disease progression in experimntal autoimmune encephalomyelitis (EAE) mouse model, Collagen-induced arthritis (CIA) mouse model, etc. .
    VAV1 degrader-3
  • HY-106835

    VUFB 16066

    COX Lipoxygenase Inflammation/Immunology
    Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis .
    Flobufen
  • HY-N6801

    Caspase Bacterial Apoptosis Antibiotic Infection Inflammation/Immunology
    Nivalenol, classified as type B trichotecenes toxins produced by Fusarium graminearum, is a fungal metabolite present in agricultural product . Nivalenol induces cell death through caspase-dependent mechanisms and via the intrinsic apoptotic pathway. Nivalenol affects the immune system, causes emesis, growth retardation, reproductive disorders and has a haematotoxic/myelotoxic effect .
    Nivalenol
  • HY-D0195

    PD-1/PD-L1 ERK mTOR Autophagy Neurological Disease Metabolic Disease
    Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion .
    Acesulfame potassium
  • HY-77048

    IRAK Inflammation/Immunology
    IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .
    IRAK-4 protein kinase inhibitor 2
  • HY-110117
    BIRT 377
    2 Publications Verification

    Integrin Interleukin Related Inflammation/Immunology
    BIRT 377 is a potent amd orally bioavailable inhibitor of the interaction between intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1), with a Ki of 25.8 nM. BIRT 377 also inhibits the production of IL-2 in vivo. BIRT 377 can be used for researching inflammatory and immune disorders .
    BIRT 377
  • HY-150745

    Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24987 is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .
    ODN 24987
  • HY-150745A

    Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24987 sodium is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 sodium can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .
    ODN 24987 sodium
  • HY-N6801R

    Caspase Bacterial Apoptosis Antibiotic Infection Inflammation/Immunology
    Nivalenol (Standard) is the analytical standard of Nivalenol. This product is intended for research and analytical applications. Nivalenol, classified as type B trichotecenes toxins produced by Fusarium graminearum, is a fungal metabolite present in agricultural product . Nivalenol induces cell death through caspase-dependent mechanisms and via the intrinsic apoptotic pathway. Nivalenol affects the immune system, causes emesis, growth retardation, reproductive disorders and has a haematotoxic/myelotoxic effect .
    Nivalenol (Standard)
  • HY-N6801S

    Isotope-Labeled Compounds Infection
    Nivalenol- 13C15 is the 13C labeled Nivalenol (HY-N6801) . Nivalenol, classified as type B trichotecenes toxins produced by Fusarium graminearum, is a fungal metabolite present in agricultural product . Nivalenol induces cell death through caspase-dependent mechanisms and via the intrinsic apoptotic pathway. Nivalenol affects the immune system, causes emesis, growth retardation, reproductive disorders and has a haematotoxic/myelotoxic effect .
    Nivalenol-13C15
  • HY-121856

    Others Inflammation/Immunology
    Flumizole, a derivative of substituted 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles, was synthesized and evaluated for its immunoregulatory and anti-inflammatory properties in animal models such as rat adjuvant-induced arthritis and mouse oxazolone-induced contact sensitivity assays. This compound class combines structural elements from flumizole and levamisole, aiming to enhance therapeutic efficacy. Symmetrically substituted 5,6-diaryl compounds with specific alkyl heteroatom or halogen substitutions showed optimal potency in the arthritis model. However, variations in activity were less consistent in the contact sensitivity assay. Flumizole and related compounds demonstrate potential as dual-action agents, targeting inflammation and immune modulation, offering promise for therapeutic development in immune-related disorders .
    Flumizole
  • HY-121892

    TNF Receptor Neurological Disease
    (Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo .
    (Z)-KC02
  • HY-109139
    Taminadenant
    1 Publications Verification

    NIR178; PBF509

    Adenosine Receptor Neurological Disease Cancer
    Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .
    Taminadenant
  • HY-111303

    Sirtuin Neurological Disease Inflammation/Immunology
    CHIC35, an analog of EX-527, is a potent and selective inhibitor of SIRT1 (IC50=0.124 µM). CHIC35 shows potential selective inhibition against SIRT1 over SIRT2 (IC50=2.8 µM) or SIRT3 (IC50>100 µM) . CHIC35 has anti-inflammatory effects and can be used for CHARGE syndrome research .
    CHIC35
  • HY-12708
    Chlorpromazine
    Maximum Cited Publications
    66 Publications Verification

    Dopamine Receptor Cytochrome P450 Autophagy 5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis .
    Chlorpromazine
  • HY-B0407A
    Chlorpromazine hydrochloride
    Maximum Cited Publications
    66 Publications Verification

    Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
    Chlorpromazine hydrochloride
  • HY-B0407AR

    Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
    Chlorpromazine (hydrochloride) (Standard)
  • HY-W041470R

    Endogenous Metabolite Metabolic Disease
    Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .
    4-Methyl-1-phenyl-2-pentanone (Standard)
  • HY-136379
    CID44216842
    1 Publications Verification

    Cdc42-IN-1

    Ras Cancer
    CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe .
    CID44216842

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: